Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hofmann, M. A.
Right arrow Articles by Nawroth, P. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hofmann, M. A.
Right arrow Articles by Nawroth, P. P.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 20, Issue 12 1880-1886, Copyright © 1997 by American Diabetes Association

ARTICLES

Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM

MA Hofmann, B Kohl, MS Zumbach, V Borcea, A Bierhaus, M Henkels, J Amiral, W Fiehn, R Ziegler, P Wahl and PP Nawroth
Department of Medicine, University of Heidelberg, Germany.

OBJECTIVE: While elevated blood levels of homocyst(e)ine represent an independent risk factor for macrovascular disease, we assessed the link between hyperhomocyst(e)inemia and diabetic microvascular diseases. RESEARCH DESIGN AND METHODS: Plasma levels of homocyst(e)ine and thrombomodulin (TM), markers of endothelial cell damage, were measured before and 3 h after oral methionine loading in 75 patients with IDDM and 40 healthy control subjects matched for sex and age. Exclusion criteria were hyperlipidemia, hypertension, smoking, or positive family history for cardiovascular disease. RESULTS: IDDM patients had higher pre- and postload plasma levels of homocyst(e)ine than did healthy control subjects (12.0 vs. 7.7 mumol/l and 27.6 vs. 16.0 mumol/l; P < 0.001). Of 75 IDDM patients, 26 had plasma homocyst(e)ine levels above the normal range (means +/- 2 SD of values obtained in the control group). These IDDM patients with hyperhomocyst(e)inemia had higher plasma TM levels (62.2 vs. 38.2 ng/ml, P < 0.001), higher albumin excretion rates (485 vs. 115 mg/l, P < 0.005), and a higher prevalence of late diabetic complications (nephropathy, 76 vs. 33%; retinopathy, 69 vs. 51%; neuropathy, 57 vs. 41%; and macroangiopathy, 57 vs. 33%) compared with IDDM patients with normal plasma homocyst(e)ine. In vitro experiments with human umbilical vein cells showed an increased release of TM into the culture supernatant only when endothelial cells were pretreated with advanced glycation end product (AGE)-albumin before L-homocystine was added. A synergistic action of homocyst(e)ine and AGEs might contribute to vascular complications in patients with diabetes. CONCLUSIONS: Hyperhomocyst(e)inemia is common in nephropathic diabetic patients and may contribute to the enhanced morbidity and mortality from cardiovascular diseases characteristically observed in IDDM patients with diabetic nephropathy.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Nutr.Home page
C. S. Hartz, K. M. Nieman, R. L. Jacobs, D. E. Vance, and K. L. Schalinske
Hepatic Phosphatidylethanolamine N-Methyltransferase Expression Is Increased in Diabetic Rats
J. Nutr., December 1, 2006; 136(12): 3005 - 3009.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. S. Abu-Lebdeh, R. Barazzoni, S. E. Meek, M. L. Bigelow, X.-M. T. Persson, and K. S. Nair
Effects of Insulin Deprivation and Treatment on Homocysteine Metabolism in People with Type 1 Diabetes
J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3344 - 3348.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Morcos, A. A.R. Sayed, A. Bierhaus, B. Yard, R. Waldherr, W. Merz, I. Kloeting, E. Schleicher, S. Mentz, R. F. Abd el Baki, et al.
Activation of Tubular Epithelial Cells in Diabetic Nephropathy
Diabetes, December 1, 2002; 51(12): 3532 - 3544.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. N. Friedman, L. G. Hunsicker, J. Selhub, A. G. Bostom, and The Collaborative Study Group
Proteinuria as a Predictor of Total Plasma Homocysteine Levels in Type 2 Diabetic Nephropathy
Diabetes Care, November 1, 2002; 25(11): 2037 - 2041.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Ratnam, K. N. Maclean, R. L. Jacobs, M. E. Brosnan, J. P. Kraus, and J. T. Brosnan
Hormonal Regulation of Cystathionine beta -Synthase Expression in Liver
J. Biol. Chem., November 1, 2002; 277(45): 42912 - 42918.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
M. Kirby
Screening for microalbuminuria
The British Journal of Diabetes & Vascular Disease, March 1, 2002; 2(2): 106 - 109.
[PDF]

Home page
 Diabetes CareHome page
G. Targher, L. Zenari, L. Bertolini, G. Falezza, M. Muggeo, and G. Zoppini
Plasma Total Homocysteine Levels Are Associated With von Willebrand Factor, Soluble Intercellular Adhesion Molecule-1, and Soluble Tumor Necrosis Factor-{alpha} Receptors in Young Type 1 Diabetic Patients Without Clinical Evidence of Macrovascular Complications
Diabetes Care, August 1, 2001; 24(8): 1496 - 1497.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. Pietzsch and A. Pixa
Determination of Total Homocysteine
Clin. Chem., August 1, 1998; 44(8): 1781 - 1782.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1997 by the American Diabetes Association.